Awakening guardian angels: drugging the p53 pathway - PubMed (original) (raw)

Review

doi: 10.1038/nrc2763.

Affiliations

Review

Awakening guardian angels: drugging the p53 pathway

Christopher J Brown et al. Nat Rev Cancer. 2009 Dec.

Abstract

Currently, around 11 million people are living with a tumour that contains an inactivating mutation of TP53 (the human gene that encodes p53) and another 11 million have tumours in which the p53 pathway is partially abrogated through the inactivation of other signalling or effector components. The p53 pathway is therefore a prime target for new cancer drug development, and several original approaches to drug discovery that could have wide applications to drug development are being used. In one approach, molecules that activate p53 by blocking protein-protein interactions with MDM2 are in early clinical development. Remarkable progress has also been made in the development of p53-binding molecules that can rescue the function of certain p53 mutants. Finally, cell-based assays are being used to discover compounds that exploit the p53 pathway by either seeking targets and compounds that show synthetic lethality with TP53 mutations or by looking for non-genotoxic activators of the p53 response.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Invest. 2008 Jan;118(1):79-88 - PubMed
    1. Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12009-14 - PubMed
    1. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3463-8 - PubMed
    1. Mol Cell Biol. 1991 Jan;11(1):12-9 - PubMed
    1. Nature. 2005 Jun 2;435(7042):677-81 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources